Balance Sheet
Cash Flow Statement
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginInterest Coverage RatioInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on SalesTimes Interest Earned

SAB Biotherapeutics (SABSW) Return on Assets (2021 - 2025)

Historic Return on Assets for SAB Biotherapeutics (SABSW) over the last 5 years, with Q3 2025 value amounting to 0.4%.

  • SAB Biotherapeutics' Return on Assets rose 3900.0% to 0.4% in Q3 2025 from the same period last year, while for Sep 2025 it was 0.4%, marking a year-over-year increase of 3900.0%. This contributed to the annual value of 0.65% for FY2024, which is 300.0% down from last year.
  • Per SAB Biotherapeutics' latest filing, its Return on Assets stood at 0.4% for Q3 2025, which was up 3900.0% from 1.2% recorded in Q2 2025.
  • SAB Biotherapeutics' 5-year Return on Assets high stood at 0.05% for Q3 2021, and its period low was 1.2% during Q2 2025.
  • Moreover, its 5-year median value for Return on Assets was 0.58% (2023), whereas its average is 0.56%.
  • The largest annual percentage gain for SAB Biotherapeutics' Return on Assets in the last 5 years was 3900bps (2025), contrasted with its biggest fall of -5900bps (2025).
  • Over the past 5 years, SAB Biotherapeutics' Return on Assets (Quarter) stood at 0.17% in 2021, then plummeted by -109bps to 0.36% in 2022, then crashed by -108bps to 0.75% in 2023, then increased by 11bps to 0.67% in 2024, then skyrocketed by 40bps to 0.4% in 2025.
  • Its Return on Assets was 0.4% in Q3 2025, compared to 1.2% in Q2 2025 and 0.93% in Q1 2025.